University home
Library
Current students
Staff intranet
Give
Skip to main content
Lambert Initiative for Cannabinoid Therapeutics

More News

16 September 2020

Australia unprepared for over-the-counter medical cannabis sales

Professor Iain McGregor from the Lambert Initiative says it is time for Australia to have a mature approach to consumer access to safe and effective cannabinoid products without a prescription.
View
08 September 2020

Medical cannabis study for spinal injury pain wins NSW Health funding

Treatments for chronic pain caused by spinal injury can cause side effects almost as difficult as the pain it is treating. Experts at the Lambert Initiative for Cannabinoid Therapeutics and Brain and Mind Centre will see if cannabidiol is an effective alternative.
View
MRI of injured spine. Shutterstock
17 June 2020

How Australians use medical cannabis since legislation: new survey

Australians report using medicinal cannabis for chronic pain, mental health and sleep with the majority sourcing cannabis illicitly, despite medicinal cannabis being legal, a new survey from the University of Sydney has revealed.
View
22 April 2020

Survey shows use of medicinal cannabis for inflammatory bowel disease

A quarter of Australians with inflammatory bowel disease report medicinal cannabis eases their symptoms, according to a new survey from the Lambert Initiative for Cannabinoid Therapeutics.
View
photo of marijuana plants
12 December 2019

Barry and Joy Lambert recognised as medicinal cannabis pioneers

Philanthropists Barry and Joy Lambert have been recognised with Honorary Fellowships by the University of Sydney for their pioneering collaboration on the establishment of the Lambert Initiative for Cannabinoid Therapeutics.
View
The Lamberts receiving their Honorary Fellowships
12 September 2019

Study casts doubt on accuracy of mobile drug testing devices

Research at the University of Sydney Lambert Initiative for Cannabinoid Therapeutics suggests the devices currently used return both false positives and false negatives.
View
A mobile drug testing bus. Source: NSW Police Facebook
16 July 2019

Cannabis treatment counters addiction: first study of its kind

A Sydney-led study published in a JAMA journal provides the first strong evidence that medicinal cannabis could reduce the rate of relapse for users of cannabis - a leading cause of drug treatment episodes in Australia.
View
cannnabis in warehouse
07 May 2019

The science of cannabis and driving

As medical cannabis becomes more readily available, it is imperative that any risks relating to driving are clarified via thorough research.
View
photo of a car driving through a busy city tunnel
18 April 2019

Cannabis use in inflammatory bowel disease: new surveys announced

Two new surveys announced for patients using or considering using medicinal cannabis to ease the symptoms of inflammatory bowel disease and for specialists caring for these patients.
View
27 March 2019

Can medicinal cannabis treat the tics in Tourette syndrome?

A pioneering clinical trial investigating medicinal cannabis as a potential treatment for people living with Tourette syndrome will be conducted by Wesley Medical Research, with the cannabis supply facilitated by Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney.
View
Photo of a cannabis plant
12 November 2018

Few doctors prescribe medical cannabis for chemo-induced nausea

Few doctors are prescribing medical cannabis to treat nausea and vomiting caused by chemotherapy because good evidence is lacking, say experts in today's Medical Journal of Australia.
View
30 January 2019

INSPIRED! $1 billion philanthropic achievement

The University of Sydney has reached its $1 billion target following an epic philanthropic campaign - the most successful of any university in the nation.
View
05 September 2018

Cannabis As Medicine Survey CAMS:18 launches

The University of Sydney is launching CAMS:18 - an online survey for people who have used medicinal cannabis in the past 12 months. This survey will provide an 'after' snapshot since legislative changes in 2016.
View
Cannabis sativa plant
14 August 2018

Illicit cannabis used for pain, mental health, sleep conditions

Australians who used illicit cannabis for medical reasons did so mainly to treat chronic pain, mental health, sleep and neurological conditions like epilepsy or seizure disorders, according to University of Sydney research.
View
Cannabis photo via Wikimedia Commons
05 July 2018

Content of illicit cannabis to treat kids with epilepsy revealed

A study of community use of medicinal cannabis to treat childhood epilepsy has found most samples contained some THC and little CBD, contrary to parents' expectations, and a majority were reported as reducing seizures.
View
04 July 2018

Australian GPs cautiously supportive of medicinal cannabis access

A majority of GPs believe medicinal cannabis should be available on prescription, bypassing the specialist system, but most lack information about how to negotiate the bureaucratic processes to meet increasing patient demand.
View
Cannabis from Wikimedia Commons
20 September 2017

Psychopharmacology professor unlearns cannabis use

Professor Iain McGregor explains how unlearning has led to a new way of seeing the world - from tennis to the perception of failure.

View
Professor of Pharmacology and cannabis researcher Iain McGregor
03 May 2017

Cannabinoid researchers join forces

The University of Sydney and Thomas Jefferson University have officially agreed to collaborate on education and research on the therapeutic uses of cannabinoids. 

View
Prof Iain McGregor
10 March 2017

Survey reveals cannabis use in Australians with epilepsy

Australians with epilepsy are turning to cannabis products when antiepileptic drug side-effects are intolerable and epilepsy uncontrolled.

View
18 August 2016

Pioneering study of cannabis extracts in treating epileptic kids

A pioneering study, the Paediatric Epilepsy Lambert Initiative Cannabinoid Analysis (PELICAN), launches today not only to identify issues facing families living with epilepsy but also to analyse cannabis products being used in the community - with the potential to uncover new and more effective medications.

View
29 March 2016

Legalising medicinal cannabis would create $100 million industry

Analysis from the University of Sydney Business School has found that legalising medicinal cannabis in Australia could create a new industry worth more than $100 million per year. 

View
26 February 2016

University partners in medical cannabis trial for chemotherapy patients

A clinical trial using a new form of cannabis developed by the University of Sydney’s Lambert Initiative will assess the use of the drug to prevent nausea and vomiting in people undergoing chemotherapy.

View
12 June 2015

Lambert donation puts Australia at forefront of medicinal cannabinoid research

A $33.7 million gift to the University of Sydney, the largest donation ever made to research, will establish the Lambert Initiative for cannabinoid therapeutics research. 

View

04 June 2020

Update on the future of International House

Director of International House, Jessica Carroll, provides an update on redevelopment plans for the current building.
20 March 2019

MBI and FAO United Nations to collaborate to combat emerging infectious diseases

The Food and Agriculture Organization of the United Nations (FAO) and The Marie Bashir Institute for Infectious Diseases and Biosecurity (MBI) have joined hands to combat the threat of emerging and re-emerging infectious diseases by increasing capacity in outbreak investigation and disease surveillance. 
26 March 2019

Global Health Security Conference

With support of our Conference Partners, the University of Sydney are hosting the first international conference on global health security in Sydney, 18-20 June 2019 - registrations are now open 
26 March 2019

Video-Reflexive Ethnography in Health Research and Healthcare Improvement: Theory and Application

This methodology has enjoyed increasing popularity among researchers internationally and has been inspired by developments across a range of disciplines: ethnography, visual and applied anthropology, medical sociology, health services research, medical and nursing education, adult education, community development, and qualitative research ethics.
06 August 2019

Eureka Prize: Act Now for TB Control

ACT Now for Tuberculosis Control – Associate Professor Greg Fox and Professor Warwick Britton from the University's Faculty of Medicine and Health and Professor Guy Marks from the University of New South Wales are award finalists for the Eureka Prize for Infectious Diseases Research.
06 August 2019

Communicable Disease Surveillance Ethics in the Age of Big Data and New Technology

Despite existing widespread digital surveillance and major potential community benefits of extending its use to communicable disease control, there is considerable public disquiet about allowing public health authorities access to personal health data.
12 August 2019

New advances in biocomplexity

Biocomplexity is the study of macro-scale complex structures and behaviours that arise from micro-scale interactions of active biological agents, across multiple levels ranging from molecules and cells to organisms and ecosystems.
17 September 2019

Detailed characterisation of the tuberculosis epidemic in Western Sydney: a descriptive epidemiological study

A new publication by members of WSLHD and MBI explores whether more detailed epidemiological analysis could provide a better overview of the local disease dynamics.
18 September 2019

Drug-resistant XDR typhoid on our doorstep

MBI researchers report Australia's first case of extensively drug-resistant (XDR) typhoid
18 September 2019

The Ruthven Blackburn Medal winner

The Medal is awarded to a senior staff member of SMS in recognition of a sustained, distinguished and notable contribution to clinical research and demonstrated commitment to mentoring junior colleagues.
Leadership for good starts here

Media

Student links

About us

Connect

Member of
Group Of Eight
APRU
Athena Swan member
Follow us_
ABN: 15 211 513 464
CRICOS Number: 00026A
TEQSA: PRV12057